E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Pantothenate kinase associated neurodegeneration (PKAN), an autosomal recessive genetic disorder, the most common form of Neurodegeneration with Brain Iron Accumulation (NBIA). It is a progressive, often fatal, neurodegenerative disease. |
Neurodegenerazione associata alla pantotenato-chinasi (PKAN), un disordine genetico autosomico recessivo, la forma pi¿ comune di neurodegenerazione con accumulo di ferro nel cervello (NBIA). E' una malattia neurodegenerativa progressiva, spesso fatale. |
|
E.1.1.1 | Medical condition in easily understood language |
Neurodegenerative disease. |
Malattia neurodegenerativa. |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Nervous System Diseases [C10] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 21.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10053643 |
E.1.2 | Term | Neurodegenerative disorder |
E.1.2 | System Organ Class | 10029205 - Nervous system disorders |
|
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The efficacy objective of this study is to evaluate the efficacy of fosmetpantotenate over 24 weeks in patients with PKAN.
The safety objective of the study is to assess the safety and tolerability of fosmetpantotenate in patients with PKAN. |
L'obiettivo di efficacia dello studio ¿ valutare l¿efficacia di fosmetpantotenato nell¿arco di 24 settimane nei pazienti con PKAN. L'obiettivo di sicurezza dello studio ¿ valutare la sicurezza e la tollerabilit¿ di fosmetpantotenato nei pazienti con PKAN. |
|
E.2.2 | Secondary objectives of the trial |
To determine the PK following multiple doses of fosmetpantotenate in patients with PKAN.
To explore potential biomarkers of disease, along with their potential response to treatment in patients with PKAN. |
Stabilire la farmacocinetica (PK) in seguito a dosi multiple di fosmetpantotenato nei pazienti con PKAN. Esplorare potenziali biomarcatori della malattia, insieme alla potenziale risposta al trattamento nei pazienti con PKAN. |
|
E.2.3 | Trial contains a sub-study | Yes |
E.2.3.1 | Full title, date and version of each sub-study and their related objectives |
Other types of substudies Specify title, date and version of each substudy with relative objectives: Additional Exploratory Assessment for Research
A blood sample will be collected at 2-3 different investigational sites from up to a total of 8 eligible patients (half adult, half pediatric) with different confirmed mutations in PANK2 to generate peripheral blood mononuclear cells (PBMCs).
To be eligible to participate, patients must have negative serologic tests for all tests outlined in Section 15.2.2 in the Clinical Trial Protocol. Patients will be required to sign a separate consent to participate in this exploratory sub-study. If a patient discontinues participation in the substudy, their participation in the main study will not be affected.
|
Altre tipologie di sottostudi specificare il titolo, la data e la versione di ogni sottostudio con i relativi obiettivi: Valutazione esplorativa aggiuntiva per ricerca
Sarà raccolto un campione di sangue in 2-3 centri sperimentali differenti, per un totale di 8 pazienti eleggibili (metà adulti, metà pediatrici) con mutazioni confermate diverse in PANK2, per generare cellule mononucleate da sangue periferico (PBMC).
Per essere idonei a partecipare, i pazienti devono avere le analisi sierologiche negative per tutte le analisi indicate in Sezione 15.2.2 del Protocollo Clinico. I pazienti dovranno firmare un consenso separato per la partecipazione a questo sotto-studio esplorativo. Se un paziente interrompe la partecipazione al sotto-studio, non ci saranno ripercussioni sulla partecipazione allo studio principale.
|
|
E.3 | Principal inclusion criteria |
- The patient has a diagnosis of PKAN as indicated by confirmed mutations in the pantothenate kinase 2 (PANK2) gene (if available, the specific mutation will be recorded). - The patient has a score of = 6 on the Pantothenate Kinase-associated Neurodegeneration Activities of Daily Living (PKAN-ADL) scale. |
- Il paziente presenta una diagnosi di PKAN, come indicato dalle mutazioni confermate nel gene della pantotenato-chinasi 2 (PANK2) (se disponibile, la specifica mutazione sarà registrata). - Il paziente presenta un punteggio =6 nella scala delle attività quotidiane svolte con neurodegenerazione associata alla pantotenato-chinasi (Pantothenate Kinase-associated Neurodegeneration Activities of Daily Living, PKAN-ADL). |
|
E.4 | Principal exclusion criteria |
- The patient has required regular or intermittent invasive ventilatory support to maintain vital signs within 24 weeks prior to randomization. - The patient has had a deep brain stimulation (DBS) device implanted within 6 months prior to screening. - The patient is unable or unwilling to remain on their pre-study dose(s) of allowed concomitant PKAN maintenance medications and therapies (including DBS settings) for the double-blind period of the study. - The patient has taken deferiprone within 30 days prior to screening. |
- Il paziente ha richiesto supporto ventilatorio invasivo regolare o intermittente per mantenere i segni vitali nelle ultime 24 settimane prima della randomizzazione. - Il paziente si è sottoposto all’impianto di un dispositivo per la stimolazione cerebrale profonda (deep brain stimulation, DBS) nei 6 mesi precedenti lo screening. - Il paziente non è in grado o non è disposto a continuare ad utilizzare la/e dose/i dei farmaci e le terapie di mantenimento concomitanti consentiti per la PKAN (incluso l'impianto del DBS) che utilizzava prima dello studio per la parte in doppio cieco dello studio. - Il paziente ha assunto deferiprone nei 30 giorni precedenti lo screening. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Primary Efficacy Endpoint - Change in the score from the PKAN-ADL Safety Endpoint - Safety and tolerability |
Endpoint di efficacia primario - Cambiamento nel punteggio PKAN-ADL Endpoint di sicurezza - Sicurezza e tollerabilità |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
For each patient, the change from Baseline in PKAN-ADL scores at Weeks 3, 6, 12, 18, and 24 of the double-blind period will be used for analysis. |
Per ogni paziente, il cambiamento del punteggio PKAN-ADL dal basale alle settimane 3, 6, 12, 18 e 24 del periodo di doppio cieco che sarà utilizzato per l'analisi. |
|
E.5.2 | Secondary end point(s) |
Secondary Efficacy Endpoint - Change in the score from Part III of the UPDRS |
Endpoint secondario di efficacia - Cambiamento nel punteggio della Parte III UPDRS (Unified Parkinson¿s Disease Rating Scale)
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Continuous measures recorded at each study visit from Baseline to the end of the 24-week double-blind period. |
Continue misure registrate ad ogni visita di studio dal basale alla fine del periodo di 24 settimane in doppio cieco. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | Yes |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | Yes |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Yes |
E.6.13.1 | Other scope of the trial description |
Tolerability |
Tollerabilit¿ |
|
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.4.1 | Number of sites anticipated in Member State concerned | 1 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 11 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Canada |
Czechia |
France |
Germany |
Italy |
Norway |
Poland |
Spain |
United Kingdom |
United States |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 6 |
E.8.9.1 | In the Member State concerned months | 5 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 6 |
E.8.9.2 | In all countries concerned by the trial months | 5 |
E.8.9.2 | In all countries concerned by the trial days | 0 |